Evidence map›Paper›PMID 40616723›Full record

ReviewInvestigational new drugs2025

The therapeutic potential of exosomes in bone cancers: osteosarcoma, chondrosarcoma, and Ewing sarcoma.

Nawfal Yousif Jamil, Mohammed S Nawrooz, Ashok Kumar Bishoyi, Suhas Ballal, Abhayveer Singh, T Krithiga, Rajashree Panigrahi, Zarrina Babamuradova, Sada Ghalib Taher, Mariem Alwan and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Investigational new drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nawfal Yousif JamilDepartment of Radiology Techniques, Health and Medical Techniques College, Alnoor University, Nineveh, Iraq. nawfal@alnoor.edu.iq.
Mohammed S NawroozCollege of Pharmacy, Ahl al Bayt University, Kerbala, Iraq.
Ashok Kumar BishoyiMarwadi University Research Center, Department of Microbiology, Faculty of Science, Marwadi University, Rajkot, Gujarat, 360003, India.
Suhas BallalDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Abhayveer SinghCentre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, Punjab, 140401, India.
T KrithigaDepartment of Chemistry, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India.
Rajashree PanigrahiDepartment of Microbiology, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, 751003, India.
Zarrina BabamuradovaDepartment of Internal Diseases of Pediatric faculty, Samarkand State Medical University, Samarkand, Uzbekistan.
Sada Ghalib TaherCollege of Dentistry, University of Thi-Qar, Thi-Qar, 64001, Iraq.
Mariem AlwanPharmacy college, Al-Farahidi University, Baghdad, Iraq.
Mahmood JawadDepartment of Pharmacy, Al-Zahrawi University College, Karbala, Iraq.
Hiba MushtaqGilgamesh Ahliya University, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma (OS), chondrosarcoma (CHS), and Ewing sarcoma (EwS) are the most common primary bone cancers (BCs). Among primary malignant tumors of the bones, OS is the most common, mainly affecting young people (4.8 per 1,000,000). The treatment of bone cancer (BC) is challenging for current medicine owing to its substantial incidence and the vast heterogeneity of malignant lesions within bone tissue. Due to the limitations of current therapies, researchers developed new strategies to treat BC. Exosomes (EXOs) play a crucial role in the development, progression, metastasis, and drug delivery of BCs, such as OS, EwS, and CHS. Hierarchical translation via tissue-specific reactions and cell-specific molecular signaling pathways accounts for the various therapeutic effects of EXOs produced from stem cells. The aim of this review is to highlight the critical role of EXOs derived from multiple cells, such as mesenchymal stem cells, immune cells, and tumor cells, in BCs, including OS, CHS, and EwS. Additionally, we provide a concise overview of how tumor-derived EXOs induce BCs. To lessen the adverse effects of EXOs on patients with BC and to provide more effective and focused treatments, it is necessary to understand these pathways. Moreover, we reviewed the potential of using EXOs as drug delivery systems for the treatment of BCs. Finally, we discussed the pros and cons of this therapeutic approach for BCs.

Indexed as

Bone NeoplasmsChondrosarcomaExosomesOsteosarcomaSarcoma, EwingAnimalsHumansBone cancersChondrosarcomaDerived exosomesEwing sarcomaMesenchymal stem cellTumor-derived exosomes

Identifiers

PMID40616723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.